Project Grant R01CA308411
Award Date 5/22/26
Completion Date 4/30/31
Dollars Obligated $683K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a $628,394 Project Grant under the Cancer Biology Research program (CFDA 93.396) on May 8, 2026, with a completion date of April 30, 2031. The award funds research to develop and validate a novel patient-derived organoid with tumor microenvironment (PDOT) co-culture system for intrahepatic cholangiocarcinoma (ICCA), a devastating liver cancer with limited therapeutic options. The...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a $2.69 million Project Grant under the Cancer Biology Research program (CFDA 93.396) on September 24, 2025, with completion scheduled for August 31, 2029. This award supports fundamental research investigating the mechanisms and impact of Neuregulin 3 (NRG3) induction in bone metastasis of breast cancer. The project will employ molecular and genetic approaches to...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $642,242 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Icahn School of Medicine at Mount Sinai to investigate the mechanisms driving brain metastasis in breast cancer models. The award, effective May 15, 2026, through April 30, 2031, supports fundamental research aimed at understanding how Neuregulin 3 (NRG3), a neuron-associated ligand, promotes the transition of cancer cells from bone...
- Federal Grant Award Summary The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai a $697,131 Project Grant under the Cancer Biology Research program (CFDA 93.396) for the period May 1, 2026 through April 30, 2031. This award supports fundamental research designed to elucidate the myeloid-stromal crosstalk mechanisms that drive immune suppression and tumor progression in colorectal cancer (CRC), particularly in microsatellite-stable cases resistant to immune checkpoint...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $169,000 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Icahn School of Medicine at Mount Sinai, effective August 1, 2025, through July 31, 2027. This research grant supports a two-year investigation into epigenetic regulation of melanoma-associated fibroblast plasticity, specifically examining how histone variant dysfunction affects the tumor microenvironment (TME). The principal...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $714,317 under the Cancer Biology Research program (CFDA 93.396) to support fundamental research on prostate cancer progression and therapeutic resistance. The five-year award, effective August 1, 2025 through July 31, 2030, funds research investigating the molecular mechanisms linking epithelial-mesenchymal transition (EMT), mesenchymal-epithelial transition...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $2.68 million Project Grant under the Cancer Biology Research program (CFDA 93.396) to Icahn School of Medicine at Mount Sinai, with an award date of August 1, 2025, and a completion date of July 31, 2030. This five-year research initiative, led by Principal Investigator James Manfredi, investigates mutant p53 protein's role in tumorigenesis, invasion, and metastasis. The program comprises four integrated...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Project Grant Award Summary Massachusetts General Hospital (MGH), through its Research Management Division, received a $707,798 project grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective April 1, 2026 through March 31, 2031. The award funds research to determine mechanisms of heterogeneous treatment response in glioblastoma (GBM), an aggressive brain tumor that typically recurs in treatment-refractory form shortly after...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a Project Grant of $194,940 on August 6, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support career development research in palliative care for glioblastoma patients. Under the direction of Dr. Rita "Caroline" Crooms, MD, MPH, this five-year award (concluding July 31, 2030) will generate evidence regarding the feasibility and acceptability of a...